Option Fees. Unless Grantee shall have otherwise elected to terminate this Option Agreement as set forth in Section 4 below, then commencing on the Effective Date and continuing on any extension of the First Option Term, Grantee shall make the payments to the Owner as set forth below (each payment an “Option Fee,” and collectively, “Option Fees”), in which case the Option Period shall continue accordingly. In addition to the foregoing, for clarity purposes, Xxxxxxx’s obligation to make the Option Fee payments shall terminate as of the date that Grantee exercises the option to lease the Property, in which event Grantee shall instead commence payment of the fees due under the Ground Lease Agreement in accordance therewith. All payments made pursuant to this Option Agreement shall be paid to the Owner on the Effective Date, or for any extension, on the date of the execution of the Option Term Extension. All payments made pursuant to this Option Agreement shall be non-refundable.
Option Fees. The option fees of [***] and [***] respectively as set forth in Article II Paragraphs B and C.
Option Fees. In full consideration for the Option granted to Amarin, within three (3) business days of execution of this Agreement by both parties, Amarin shall pay to Elan a non-refundable, non-creditable option fee of One Hundred Thousand Dollars ($100,000).
Option Fees. (a) Each Party acknowledges that Licensee has previously delivered an Option Notice for the EBV Autologous Option and has paid to Institute a fee of [***] (the “Option Fee”). The Option Fee is nonrefundable and non-creditable against any other amounts once paid and is not in any way contingent on use or productivity of the underlying technology and know-how related to the EBV Autologous Option.
(b) Within ten (10) days following Licensee’s delivery of a [***] Notice for the [***] Program, Licensee shall pay to Institute a fee of [***] (the “[***] Fee”). The [***] Fee is non-refundable and non-creditable against any other amounts once paid and is not in any way contingent on use or productivity of the underlying technology and know-how related to the [***] Program. 9745235_1.docx
Option Fees. In consideration for the option granted in Section 7.1 ----------- above, Glaxo shall pay to MEGABIOS the amounts set forth below in each of the years of the Research Term so indicated: [*]=CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. Year 1 [ * ] Year 2 [ * ] Year 3 [ * ] Year 4 [ * ] Year 5 [ * ] Such amounts shall be payable in advance, 30 days prior to the commencement of the relevant Year for which payment is due, with "Year 1" commencing on the Effective Date and each "Year" thereafter commencing upon the respective anniversary thereof.
Option Fees. (i) Discovery agrees to pay to XXXX option fees in accordance with the following table to add Belgium, France, Germany, Italy, the Netherlands, Switzerland and the United Kingdom to the Licensed Territory: Event License Fee ----- ----------- Execution of this Agreement $ 200,000 Upon exercise of the option in Europe but in $ 200,000 no event later than January 1, 2002 (Discovery must exercise option if any development work is done in Europe) Upon Date of NDA Submission with the first $1,000,000 European country's equivalent of the FDA The above named countries shall be considered added to the license granted hereunder by expansion of the Licensed Territory after payment of the $200,000 installment due upon exercise of the option to expand the Licensed Territory. All fees due under this Section 3C are payable only once, regardless of the number of Products, or submissions to the European equivalent of the FDA.
(ii) Discovery agrees to pay an option fee of $500,000 on or before January 1, 2002 to add Australia, New Zealand, Ireland, Finland, Denmark, Norway, Sweden, Greece and any and all remaining countries of the world to the Licensed Territory except Argentina, Spain, Portugal, Korea and Japan.
(iii) In Argentina, Spain, Portugal and Korea, Discovery shall have the right to prior review and approval of any license agreement to be entered into by XXXX under the Licensed Patents or the Use Patents in the Licensed Field. Such approval shall not be unreasonably withheld. Such license agreements shall provide that the licensees for any of the territories of Argentina, Spain, Portugal and Korea are (i) prohibited from directly or indirectly making any sales or marketing products containing the Compound outside of such licensee's territory and (ii) required to xxxx products containing the Compound as not for resale outside of such licensee's territories. In the event that any of such licensees violates the foregoing prohibition or obligation, XXXX shall enforce its contractual rights against such licensee to the greatest extent permitted under applicable law. Additionally, XXXX may only enter into a license with the following parties in the following countries: Argentina - Gador Spain and Portugal - FAES Korea - YuYu If XXXX and the above named companies are unable to reach agreement on a license then Discovery shall have the option to obtain a license under the Licensed Patents and the Use Patents in the Licensed Field in Argentina, Spain, Portugal and Korea un...
Option Fees. In partial consideration for the Option, Sucampo shall pay CPP Seven Million Five Hundred Thousand U.S. Dollars ($7,500,000) as follows:
Option Fees. For each single QBI Option requested by QBI and granted by Atugen for the option period, QBI agrees to pay Atugen a non-refundable option fee as follows:
3.7.1 [ * ] if at the time the QBI Option is granted [ * ], a sum which shall be increased to
3.7.2 [ * ] if (i) [ * ] at the time the relevant QBI Option is granted or (ii) if [ * ] but prior to [ * ] with respect to the relevant QBI Target. The difference due according to 3.7.2 (ii) shall be [ * ] from receipt by QBI of Atugen’s notice of [ * ].. The option fee shall be payable within [ * ] from delivery of the respective QBI Option Notice.
Option Fees. In order to initially exercise the Option, IC shall send to AMBI a notice of Option exercise and pay to AMBI $25,000 on or before August 1, 2000.
Option Fees. Upon exercise of its Option for a Program, Celgene shall, within [***] after the Implementation Date of the applicable Development & Commercialization Agreement, pay to Jounce an Option exercise payment in the applicable amount as set forth below for such Program:
6.4.1 For the ICOS Activator Program, an amount equal to the sum of [***] and the Allocable Costs (as defined in the Jounce Lead Co-Development and Co-Commercialization Agreement);
6.4.2 For the Lead Program, an amount equal to the sum of [***] and the Allocable Costs (as defined in the Celgene Lead Co-Development and Co-Commercialization Agreement); and
6.4.3 For the PD-1 Activator Program, an amount equal to [***];
6.4.4 For the First Other Program, a one-time payment in an amount equal to [***];
6.4.5 For the Other Program that follows the First Other Program, a one-time CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. payment in an amount equal to [***]; and
6.4.6 For each additional Other Program, an amount equal to [***] for each such Option exercised.
